That said, Recursion doesn't have a single therapy on the market yet. Over the past four years, the company has made little ...

Small-cap biotech companies can deliver outsized returns over the long run if they develop breakthrough medicines that go on to generate massive sales. However, some of these smaller drugmakers aren't ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.

Recursion says it intends to offer and sell $200 million worth of its common stock in an underwritten public offering. Recursion had $296.3 million in cash and cash equivalents as of March 31.

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The opportunity to explore a multi-genre universe in innovative ways is extremely exciting. Matt ...

Recursion Pharmaceuticals, Inc. ( NASDAQ: RXRX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT ...

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...

Recursion is seeking to revolutionize the way we develop drugs. If it's successful, the biotech will reap immense benefits. However, the stock is somewhat risky for now. The process of developing ...

Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key to ...